Please refer the attached intimation.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Transchem Limited's Board on Feb 7, 2026 approved the unaudited financial results for the quarter and nine months ended December 31, 2025. Total income for 9M FY26 stood at Rs 555.98 lakhs, down roughly 20% from Rs 697.08 lakhs in 9M FY25, with the company largely reliant on 'other income' rather than operating revenue (which was just Rs 20.60 lakhs in Q3). Net profit for 9M FY26 fell sharply to Rs 220.19 lakhs from Rs 449.61 lakhs a year ago, a drop of about 51% YoY, taking basic EPS to Rs 1.80 vs Rs 3.67 in 9M FY25. Standalone Q3 FY26 numbers were Rs 224.78 lakhs in total income and Rs 52.94 lakhs in net profit. Auditor M/s Mathur & Co. issued a clean (unqualified) limited review report. Separately, shareholders at an EGM on Dec 20, 2025 approved issuance of up to 6.15 crore warrants on a preferential basis at Rs 75 each, which could raise roughly Rs 46 crore in fresh capital once BSE in-principle approval is received.
Sharp YoY declines in both top line and bottom line, along with significant margin compression, may weigh on stock sentiment in the near term. However, the proposed ~Rs 46 crore preferential warrant issue could strengthen the company's capital base once completed.